:Biostrophin

{{Multiple issues|

{{update|date=March 2015}}

{{Refimprove|date=November 2011}}

}}

Biostrophin is a drug which may serve as a vehicle for gene therapy, in the treatment of Duchenne and Becker muscular dystrophy.{{cite journal |pmid=16391721 |date=Oct 2005 |vauthors=Khurdayan VK, Bozzo J, Prous JR |title=Chronicles in drug discovery |volume=18 |issue=8 |pages=517–522 |issn=0214-0934 |journal=Drug News & Perspectives |doi=10.1358/dnp.2005.18.8.953409}}

As mutations in the gene which codes for the protein dystrophin is the underlying defect responsible for both

disorders, biostrophin will deliver a genetically-engineered, functional copy of the gene at the molecular level to affected muscle cells. Dosage, as well as a viable means for systemic release of the drug in patients, is currently being investigated with the use of both canine and primate animal models.http://www.ncbiotech.org/news_and_events/industry_news/duchenne.html Dec 2006 {{webarchive |url=https://web.archive.org/web/20071017190839/http://www.ncbiotech.org/news_and_events/industry_news/duchenne.html |date=October 17, 2007 }}

Biostrophin is being manufactured by Asklepios BioPharmaceuticals, Inc., with funding provided by the Muscular Dystrophy Association.{{cite news|url=http://www.businesswire.com/news/home/20060928005134/en/Asklepios-Biopharmaceutical-Announces-Cross-License-GlaxoSmithKline|title=Asklepios Biopharmaceutical, Inc. Announces Cross License with GlaxoSmithKline|date=2006-09-28}}